
2025-02 Primary Care Update Orlando
Dr. Reamer L. Bushardt, PharmD, PA-C, DFAAPA
DFAAPA Professor, Provost and Vice President for Academic Affairs, Massachusetts General Hospital Institute for Health Professions, Mass General Brigham, Boston, MA. PA in Primary Care. Editor-in-Chief Emeritus, Journal of the American Academy of PAs. Principal Investigator Expansion of Practitioner Education in Substance Use Disorders Program, U.S. Substance Abuse and Mental Health Services Administration (SAMHSA).
Price: $99 for 10 Contact Hours
Learning Objectives
Optimizing Drug Therapy and Avoiding Drug Injury in Older Adults
Discuss key physiologic and common pathophysiologic changes of aging that impact drug therapy.
Apply age-sensitive principles for medication dosing and management to patient scenarios.
List nine key questions useful for identifying and managing inappropriate polypharmacy (i.e. unnecessary medication use) in older adults.
Apply practical tools to screen and appropriately manage complex drug regimens among older adults with or at-risk for drug injury.
Discuss high risk drug-drug and drug-dietary supplement interactions commonly encountered in primary care, including best practices in identifying and managing related toxicities.
Best Practices in Prescribing Opioids: A Regulatory Perspective
Describe evolving opioid prescribing and regulatory practices in the United States.
Discuss recently released opioid prescribing guidelines, highlighting the relevance to outpatient treatment of pain.
Describe best practices and patient care resources for managing patients with nonmalignant pain, highlighting guidance from a regulatory perspective.
Reflect on challenges in prescribing opioids and other controlled substances with real-world practice examples.
Pharmacotherapy for Major Depression: A Case-Based Approach:
Discuss pharmacologic management options within clinical cases of patients with depression.
Relate physiologic and pathophysiologic alternations of brain neurochemistry to symptoms of depression, including the genetic link and molecular basis of injury.
Apply clinical practice guidelines and expert recommendations for antidepressant therapies.
Describe key parameters for medications used to treat depression, including mechanism, safety, tolerability, efficacy, price, and simplicity of use.
Managing Anxiety and Sleep Disorders: Drug and Non-Pharmacologic Considerations
Describe signs and symptoms of common sleep disorders and anxiety disorders with a focus on older adults.
Discuss common anxiety disorders, including the neurobiological basis of disease, clinical presentation, assessment, and approach to treatment.
Recognize evidence-based treatments for insomnia and common anxiety disorders, including lifestyle, behavioral, and pharmacologic interventions.
Identify key parameters that warrant referral to specialty care for individuals with insomnia and/or anxiety disorders.
Mood Stabilizers in Primary Care: Off Label Prescribing
Discuss “off-label” use of mood stabilizers and psychotropic agents for agitation, restlessness, insomnia, and other behavioral symptoms.
Differentiate commonly prescribed agents by pharmacologic class, mechanism of action, pharmacokinetic factors, indications/uses, as well as tolerability, and efficacy.
Apply best practices in prescribing and shared decision making when considering “off label” use of drugs in a case scenario involving dementia and brain injury.
Consider steps to optimize benefits and reduce risks to patients, while prescribing with liability authority.
Prevention and Management of Osteoporosis: An Evidence-Based Approach:
1. Define treatment goals for patients with or at-risk for osteoporosis.
2. Relate treatment strategies to empiric evidence regarding fracture prevention and treatment.
3. Develop a prevention and monitoring plan for patients at-risk for osteoporosis.
4. Describe pertinent pharmacologic parameters related to pharmaceuticals used in the prevention and treatment of osteoporosis.
Best Practices in Chronic Kidney Disease: Highlights from Latest Guidelines
1. Describe latest evidence and expert consensus guidance for the evaluation and risk assessment of individuals with CKD.
2. Discuss medications used to delay CKD progression and manage its complications, including mechanism, safety, tolerability, efficacy, price, and simplicity of use.
3. Discuss strategies to identify and manage cardiovascular risk in individuals with CKD.
4. Describe key recommenations
Conference Credit
PHARMACISTS :University Learning Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. These programs are accredited for pharmacists.
Session |
Contact Hours |
ACPE UAN |
Activity |
Session 1 |
3 |
0741-0000-24-007-H01-P |
APPLICATION |
Session 2 | 2 | 0741-0000-24-008-H01-P | APPLICATION |
Session 3 | 3 | 0741-0000-23-009-H01-P | APPLICATION |
NURSE PRACTITIONERS/ NURSES: This course provides 8 contact hours to fulfill the pharmacotherapeutics/ pharmacology requirements for American Nurses Credentialing Center (ANCC) Category 1 Continuing Education Hours for certification renewal as well as other Nurse Practitioner credentialing organizations. The same hours submitted to renew certification may be submitted to a State Board of Nursing for re-licensure. American Nurses Credentialing Center (ANCC) accepts formally approved continuing education sponsored by organizations accredited or approved by the Accreditation Council for Pharmacy Education (ACPE). .
PHYSICIANS: This CME program offers Category 2 credit.
PHYSICIAN ASSISTANTS: This CME program offers Category 2 credit.
CONSULTANT PHARMACISTS: Some consultant pharmacist boards accept University Learning Systems courses for recertification either as is or with board approval. Please contact your board regarding course approval and ULS with any questions.
CANADIAN PHARMACISTS: Canadian Council on Continuing Education in Pharmacy (CCCEP) accepts courses accredited by the Accreditation Council for Pharmacy Education (ACPE). This credit is applicable to health professionals who may require pharmacology credit.
CANADIAN PHYSICIANS: Members of the College of Family Physicians of Canada are eligible to receive up to 15 MAINPRO-M1 credits for participation in this activity due to reciprocal agreement with the American Academy of Family Physicians.
OTHER HEALTH PROFESSIONALS: Contact your respective board regarding approval